WO2012058312A1 - Artificial scab for use in an airway - Google Patents

Artificial scab for use in an airway Download PDF

Info

Publication number
WO2012058312A1
WO2012058312A1 PCT/US2011/057893 US2011057893W WO2012058312A1 WO 2012058312 A1 WO2012058312 A1 WO 2012058312A1 US 2011057893 W US2011057893 W US 2011057893W WO 2012058312 A1 WO2012058312 A1 WO 2012058312A1
Authority
WO
WIPO (PCT)
Prior art keywords
chitosan
wound
composition according
surgical site
oxidized
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2011/057893
Other languages
English (en)
French (fr)
Inventor
James B. Hissong
Matthew F. Myntti
Jennifer G. Medina
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Medtronic Inc
Original Assignee
Medtronic Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medtronic Inc filed Critical Medtronic Inc
Priority to ES11787959.3T priority Critical patent/ES2543019T3/es
Priority to EP11787959.3A priority patent/EP2632502B1/en
Priority to AU2011319947A priority patent/AU2011319947B2/en
Priority to CA2814148A priority patent/CA2814148C/en
Priority to JP2013536780A priority patent/JP5937094B2/ja
Publication of WO2012058312A1 publication Critical patent/WO2012058312A1/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L24/00—Surgical adhesives or cements; Adhesives for colostomy devices
    • A61L24/04—Surgical adhesives or cements; Adhesives for colostomy devices containing macromolecular materials
    • A61L24/043—Mixtures of macromolecular materials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
    • A61L26/0009—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form containing macromolecular materials
    • A61L26/0052—Mixtures of macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
    • C08L1/00—Compositions of cellulose, modified cellulose or cellulose derivatives
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
    • C08L3/00—Compositions of starch, amylose or amylopectin or of their derivatives or degradation products
    • C08L3/04—Starch derivatives, e.g. crosslinked derivatives
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
    • C08L3/00—Compositions of starch, amylose or amylopectin or of their derivatives or degradation products
    • C08L3/04—Starch derivatives, e.g. crosslinked derivatives
    • C08L3/10—Oxidised starch
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
    • C08L5/00—Compositions of polysaccharides or of their derivatives not provided for in groups C08L1/00 or C08L3/00
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
    • C08L5/00—Compositions of polysaccharides or of their derivatives not provided for in groups C08L1/00 or C08L3/00
    • C08L5/08—Chitin; Chondroitin sulfate; Hyaluronic acid; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices

Definitions

  • substantially dry when used in reference to a solvatable powder means the powder contains a sufficiently low amount of water to be free-flowing, for example less than 10% or less than 5% water.
  • the applied dry particles appear to attain increased tissue adhesion. This increase may be due to a delay in the competing inter-particle crosslinking reaction afforded by the application of the chitosan and oxidized polysaccharide as mixed but substantially dry powdered particles rather than as fully solvated species.
  • compositions are sufficiently free of collagen (e.g., containing no collagen at all) so as to be saleable worldwide for use without restriction in humans.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Polymers & Plastics (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Surgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Materials Engineering (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Hematology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Otolaryngology (AREA)
  • Virology (AREA)
  • Diabetes (AREA)
  • Transplantation (AREA)
  • Medicinal Preparation (AREA)
  • Materials For Medical Uses (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PCT/US2011/057893 2010-10-27 2011-10-26 Artificial scab for use in an airway Ceased WO2012058312A1 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
ES11787959.3T ES2543019T3 (es) 2010-10-27 2011-10-26 Costra artificial para uso en una vía respiratoria
EP11787959.3A EP2632502B1 (en) 2010-10-27 2011-10-26 Artificial scab for use in an airway
AU2011319947A AU2011319947B2 (en) 2010-10-27 2011-10-26 Artificial scab for use in an airway
CA2814148A CA2814148C (en) 2010-10-27 2011-10-26 Artificial scab for use in an airway
JP2013536780A JP5937094B2 (ja) 2010-10-27 2011-10-26 気道に使用する人口かさぶた

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US40739110P 2010-10-27 2010-10-27
US61/407,391 2010-10-27

Publications (1)

Publication Number Publication Date
WO2012058312A1 true WO2012058312A1 (en) 2012-05-03

Family

ID=45034163

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2011/057893 Ceased WO2012058312A1 (en) 2010-10-27 2011-10-26 Artificial scab for use in an airway

Country Status (7)

Country Link
US (2) US9700648B2 (enExample)
EP (1) EP2632502B1 (enExample)
JP (1) JP5937094B2 (enExample)
AU (1) AU2011319947B2 (enExample)
CA (1) CA2814148C (enExample)
ES (1) ES2543019T3 (enExample)
WO (1) WO2012058312A1 (enExample)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104744723A (zh) * 2015-03-10 2015-07-01 江苏卓见医疗用品有限公司 壳聚糖医用材料及其制备方法和用途
JP2016508431A (ja) * 2013-02-28 2016-03-22 メドトロニック・ゾーメド・インコーポレーテッド 生体材料送達デバイス
JP2016508428A (ja) * 2013-02-28 2016-03-22 メドトロニック・ゾーメド・インコーポレーテッド 生体材料送達デバイス
WO2019140181A1 (en) * 2018-01-12 2019-07-18 Boston Scientific Scimed, Inc. Powder for achieving hemostasis
NL2022788B1 (en) * 2019-03-22 2020-09-28 No Ceuticals B V Chitosan nitrate for use as a nitric oxide donor (NO donor)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8932560B2 (en) 2007-09-04 2015-01-13 University of Maryland, College Parke Advanced functional biocompatible polymeric matrix used as a hemostatic agent and system for damaged tissues and cells
EP2498820B1 (en) 2009-11-13 2019-01-09 University of Maryland, College Park Advanced functional biocompatible foam used as a hemostatic agent for compressible and non-compressible acute wounds
US9616088B2 (en) 2013-03-13 2017-04-11 Gel-E, Inc. Advanced functional biocompatible polymer putty used as a hemostatic agent for treating damaged tissue and cells
US10183132B2 (en) * 2014-09-11 2019-01-22 Ethicon Llc Methods and devices for co-delivery of liquid and powdered hemostats and sealants
US10576099B2 (en) 2016-10-21 2020-03-03 Covidien Lp Injectable scaffold for treatment of intracranial aneurysms and related technology
US10835635B2 (en) 2017-08-04 2020-11-17 Hcs Innovation, Llc Natural polymer based tissue adhesive with healing promoting properties
US11571492B2 (en) 2017-08-04 2023-02-07 Hcs Innovation, Llc Natural polymer-based tissue adhesive with healing-promoting properties
US12102729B2 (en) 2017-08-04 2024-10-01 Hcs Innovation, Llc Natural polymer-based tissue adhesive with healing-promoting properties
US10517988B1 (en) 2018-11-19 2019-12-31 Endomedix, Inc. Methods and compositions for achieving hemostasis and stable blood clot formation
WO2020106703A1 (en) 2018-11-19 2020-05-28 Endomedix, Inc. Methods and compositions for achieving hemostasis and stable blood clot formation
CN109498833B (zh) * 2018-12-12 2021-05-28 济南格莱威医疗科技有限公司 一种医用可吸收多聚糖复合材料及其用途
WO2021092618A1 (en) 2019-11-04 2021-05-14 Covidien Lp Devices, systems, and methods for treatment of intracranial aneurysms
WO2022198208A1 (en) 2021-03-16 2022-09-22 Covidien Lp Injectable biopolymer compositions and associated systems and methods
JP7694927B2 (ja) 2021-09-10 2025-06-18 コウシュウ・バイオシール・バイオテック・カンパニー・リミテッド 手術部位での出血を制御し、組織を封止するための、止血薬粉末送達及び液体送達複合デバイス

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0659440A1 (en) * 1993-12-23 1995-06-28 JOHNSON & JOHNSON MEDICAL, INC. Calcium-modified oxidized cellulose hemostat
WO2003020771A1 (en) 2001-08-31 2003-03-13 Mucobiomer Biotechnologische Forschungs- Und Entwicklungs Gesmbh Chitosan-thio-amidine conjugates and their cosmetic as well as pharmaceutic use
GB2393120A (en) * 2002-09-18 2004-03-24 Johnson & Johnson Medical Ltd Compositions for wound treatment
US20070264310A1 (en) 2006-05-10 2007-11-15 Medtronic, Inc. Solvating system and sealant for medical use in the middle or inner ear
US20080195037A1 (en) 2007-02-08 2008-08-14 James Britton Hissong Film forming polymeric sealant for medical use
WO2009132225A2 (en) * 2008-04-24 2009-10-29 Medtronic, Inc. Rehydratable polysaccharide particles and sponge
US20090270346A1 (en) 2008-04-24 2009-10-29 Medtronic, Inc. Protective gel based on chitosan and oxidized polysaccharide
US20090291912A1 (en) 2008-04-24 2009-11-26 Medtronic, Inc. Chitosan-containing protective composition

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2772999A (en) * 1952-06-06 1956-12-04 Johnson & Johnson Hemostatic surgical compositions and dressings
US4952618A (en) * 1988-05-03 1990-08-28 Minnesota Mining And Manufacturing Company Hydrocolloid/adhesive composition
JP3636468B2 (ja) * 1994-07-01 2005-04-06 バクスター、インターナショナル、インコーポレイテッド 生化学的にバランスさせた腹膜透析溶液
WO1998022114A1 (en) * 1996-11-15 1998-05-28 Dumex-Alpharma A/S A method for promoting tissue repair
US6703047B2 (en) 2001-02-02 2004-03-09 Incept Llc Dehydrated hydrogel precursor-based, tissue adherent compositions and methods of use
US20060004314A1 (en) 2001-06-14 2006-01-05 Hemcon, Inc. Antimicrobial barriers, systems, and methods formed from hydrophilic polymer structures such as chistosan
DE10152407A1 (de) 2001-10-24 2003-05-08 Aesculap Ag & Co Kg Zusammensetzung aus mindestens zwei biokompatiblen chemisch vernetzbaren Komponenten
US6669695B2 (en) * 2002-01-15 2003-12-30 Giancarlo Luigi Multifunctional electrosurgical instrument
JP4321007B2 (ja) 2002-04-25 2009-08-26 凸版印刷株式会社 多糖類複合体及びその製造方法
US20040052850A1 (en) 2002-09-13 2004-03-18 Kemal Schankereli Proteinaceous hemostatic tissue sealant
KR20060003872A (ko) 2003-04-04 2006-01-11 티슈메드 리미티드 조직-부착성 제형물
US7834065B2 (en) * 2005-01-31 2010-11-16 Bmg Incorporated Medical-use two part reactive adhesive and medical-use resin having self-degradation property
US20090062233A1 (en) * 2007-08-09 2009-03-05 Xin Ji Modified starch material of biocompatible hemostasis

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0659440A1 (en) * 1993-12-23 1995-06-28 JOHNSON & JOHNSON MEDICAL, INC. Calcium-modified oxidized cellulose hemostat
WO2003020771A1 (en) 2001-08-31 2003-03-13 Mucobiomer Biotechnologische Forschungs- Und Entwicklungs Gesmbh Chitosan-thio-amidine conjugates and their cosmetic as well as pharmaceutic use
GB2393120A (en) * 2002-09-18 2004-03-24 Johnson & Johnson Medical Ltd Compositions for wound treatment
US20070264310A1 (en) 2006-05-10 2007-11-15 Medtronic, Inc. Solvating system and sealant for medical use in the middle or inner ear
US20080195037A1 (en) 2007-02-08 2008-08-14 James Britton Hissong Film forming polymeric sealant for medical use
WO2009132225A2 (en) * 2008-04-24 2009-10-29 Medtronic, Inc. Rehydratable polysaccharide particles and sponge
US20090270346A1 (en) 2008-04-24 2009-10-29 Medtronic, Inc. Protective gel based on chitosan and oxidized polysaccharide
WO2009132229A2 (en) 2008-04-24 2009-10-29 Medtronic, Inc. Cold ionizing radiation sterilization
US20090291912A1 (en) 2008-04-24 2009-11-26 Medtronic, Inc. Chitosan-containing protective composition

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
BERNKOP-SCHNÜRCH ET AL.: "Thiomers: Preparation and in vitro evaluation ofa mucoadhesive nanoparticulate drug delivery system", INTERNATIONAL JOURNAL OF PHARMACEUTICS, vol. 317, 2006, pages 76 - 81
BERNKOP-SCHNURCH: "Thiomers: A new generation ofmucoadhesive polymers", ADVANCED DRUG DELIVERY REVIEWS, vol. 57, 2005, pages 1569 - 1582
KRAULAND ET AL.: "Viscoelastic Properties of a New in situ Gelling Thiolated Chitosan Conjugate", DRUG DEVELOPMENT AND INDUSTRIAL PHARMACY, vol. 31, 2005, pages 885 - 893, XP009118552, DOI: doi:10.1080/03639040500271985
ROLDO ET AL.: "Mucoadhesive thiolated chitosans as platforms for oral controlled drug delivery: synthesis and in vitro evaluation", EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS, vol. 57, 2004, pages 115 - 121, XP004518758, DOI: doi:10.1016/S0939-6411(03)00157-7
WENG ET AL.: "Rheological Characterization of in Situ Crosslinkable Hydrogels Formulated from Oxidized Dextran and N-Carboxyethyl Chitosan", BIOMACROMOLECULES, vol. 8, 2007, pages 1109 - 1115, XP008132292, DOI: doi:10.1021/bm0610065

Cited By (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016508431A (ja) * 2013-02-28 2016-03-22 メドトロニック・ゾーメド・インコーポレーテッド 生体材料送達デバイス
JP2016508428A (ja) * 2013-02-28 2016-03-22 メドトロニック・ゾーメド・インコーポレーテッド 生体材料送達デバイス
CN104744723A (zh) * 2015-03-10 2015-07-01 江苏卓见医疗用品有限公司 壳聚糖医用材料及其制备方法和用途
US11701448B2 (en) 2018-01-12 2023-07-18 Boston Scientific Scimed, Inc. Powder for achieving hemostasis
CN111587129A (zh) * 2018-01-12 2020-08-25 波士顿科学国际有限公司 实现止血的粉末
KR20200108020A (ko) 2018-01-12 2020-09-16 보스톤 싸이엔티픽 싸이메드 인코포레이티드 지혈을 달성하기 위한 분말
US10786596B2 (en) 2018-01-12 2020-09-29 Boston Scientific Scimed, Inc. Powder for achieving hemostasis
WO2019140181A1 (en) * 2018-01-12 2019-07-18 Boston Scientific Scimed, Inc. Powder for achieving hemostasis
EP4218844A1 (en) * 2018-01-12 2023-08-02 Boston Scientific Scimed, Inc. Powder for achieving hemostasis
AU2019207880B2 (en) * 2018-01-12 2024-04-11 Boston Scientific Scimed, Inc. Powder for achieving hemostasis
KR102712081B1 (ko) 2018-01-12 2024-10-02 보스톤 싸이엔티픽 싸이메드 인코포레이티드 지혈을 달성하기 위한 분말
KR20240148929A (ko) 2018-01-12 2024-10-11 보스톤 싸이엔티픽 싸이메드 인코포레이티드 지혈을 달성하기 위한 분말
NL2022788B1 (en) * 2019-03-22 2020-09-28 No Ceuticals B V Chitosan nitrate for use as a nitric oxide donor (NO donor)
WO2020197385A1 (en) * 2019-03-22 2020-10-01 No-Ceuticals B.V. Chitosan nitrate for use as a nitric oxide donor (no donor)

Also Published As

Publication number Publication date
JP2013540821A (ja) 2013-11-07
AU2011319947A1 (en) 2013-05-09
US10279072B2 (en) 2019-05-07
US9700648B2 (en) 2017-07-11
US20170304487A1 (en) 2017-10-26
JP5937094B2 (ja) 2016-06-22
EP2632502A1 (en) 2013-09-04
CA2814148C (en) 2018-11-06
CA2814148A1 (en) 2012-05-03
AU2011319947B2 (en) 2015-01-22
EP2632502B1 (en) 2015-05-06
ES2543019T3 (es) 2015-08-14
US20120108509A1 (en) 2012-05-03

Similar Documents

Publication Publication Date Title
US10279072B2 (en) Artificial scab for use in an airway
US9333220B2 (en) Method for treating the ear, nose, sinus or throat
US8530632B2 (en) Chitosan-containing protective composition
US10420794B2 (en) Polysaccharide particle mixture
US9198997B2 (en) Rehydratable thiolated polysaccharide particles and sponge

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11787959

Country of ref document: EP

Kind code of ref document: A1

DPE1 Request for preliminary examination filed after expiration of 19th month from priority date (pct application filed from 20040101)
ENP Entry into the national phase

Ref document number: 2814148

Country of ref document: CA

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2013536780

Country of ref document: JP

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 2011319947

Country of ref document: AU

Date of ref document: 20111026

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2011787959

Country of ref document: EP